This is a high-level, clinical reference by world-class specialists on the efficacy of hormone replacement therapy for the primary prevention of cardiovascular risk in postmenopausal women. Specific chapters cover pulsed estrogen therapy with Aerodiol and cardiovascular risk assessment in postmenopausal hormone replacement therapies such as Livial (tibolone). This volume is based on the formal presentations and subsequent discussions that took place at the International Menopause Society specially convened Expert Workshop on Hormone Replacement Therapy and Cardiovascular Disease, London, UK, October 13-16, 2000.
Rezensionen / Stimmen
'A tremendous aid for any physician who wants to be able to feel knowledgeable about the risks and benefits of hormone replacement therapy for prevention of heart disease ... It is a relevant and valuable survey of the current status of research and practice into this important and fascinating area.' - Doody's Notes
Sprache
Verlagsort
Verlagsgruppe
Zielgruppe
Gewicht
ISBN-13
978-1-84214-038-3 (9781842140383)
Copyright in bibliographic data is held by Nielsen Book Services Limited or its licensors: all rights reserved.
Schweitzer Klassifikation
List of principal contributors. Introduction. Section I Cardiovascular disease: basic pathophysiological mechanisms. Trends in mortality rates for cardiovascular and cerebrovascular diseases in developed countries. Cardiovascular aging in women andmen in the absence of clinical disease. Lipid metabolism. Diabetes, obesity and cardiovascular disease. Endothelial function in hypertension: role of gender. Venous thromboembolism and hormone replacement therapy. Acute coronary syndromes in women.Section II Cardiovascular disease: basic mechanisms of sex steroid action. Estrogen receptors-b and women's health. Molecular biology of selective estrogen receptor modulators. The estrogen receptor knock-out mouse model. Sex steroids and thecardiovascular system: molecular mechanisms of action. Progestins and the cardiovascular system. Sex steroids and the cardiovascular system in vivo: actions in animal models. Sex steroids and the cardiovascular system: in vivo actions in humans. Sexsteroids and blood coagulation. Lipoprotein-associated estrogen: the role of lecithin: cholesterol acyltransferase and cholesteryl ester transfer protein. Section III Cardiovascular effects of available hormone replacement therapy. Cardiovascular effectsof hormone replacement therapy: what factors may influence risk Effects of transdermal hormone replacement therapy on cardiovascular outcomes: epidemiological evidence. Pulsed estrogen therapy: Aerodiol . Cardiovascular effects of raloxifene: data frompreclinical studies and clinical trials in postmenopausal women. Cardiovascular risk assessment for postmenopausal hormone replacement therapies such as tibolone (Livial ). Section IV Clinical effects of hormone replacement therapy: primary and secondaryprevention of cardiovascular disease. Hormone replacement therapy and myocardial infarction. Hormonal replacement therapy, venous thromboembolism and stroke. Index.
